NYMX - Nymox Pharmaceutical Corporation
| Previous Close | 1.74 |
| Open | 1.75 |
| Bid | 1.63 x 4000 |
| Ask | 2.90 x 1400 |
| Day's Range | 1.67 - 1.80 |
| 52 Week Range | 1.61 - 4.60 |
| Volume | 58,786 |
| Avg. Volume | 132,069 |
| Market Cap | 102.656M |
| Beta (3Y Monthly) | -0.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.23 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.25 |
- GlobeNewswire•9 days ago
Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
Regulatory Filings for Fexapotide in BPH: The Company is pleased with the progress its regulatory filings for its lead product, Fexapotide Triflutate, are making for BPH (Benign Prostatic Hyperplasia) both in Europe and the United States. The successful financing earlier this summer has allowed the Company to expand its work with top-end regulatory teams on both continents. Quality Control: The Company has augmented its internal quality control activities with an expanded team and a new office located in Orange County, California.
- GlobeNewswire•11 days ago
Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy
Nymox Pharmaceutical Corporation (NYMX) is pleased to announce today important new long-term clinical trial results from the Company's 146 patient Phase IIb NX03-0040 Fexapotide (FT) U.S. study for low grade localized prostate cancer. Paul Averback, CEO of Nymox, said, "These exciting new results confirm and expand the evidence for the beneficial long-term effect of a virtually painless and safe minimal administration of Fexapotide Triflutate to men with low grade localized prostate cancer.
- GlobeNewswire•17 days ago
Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
HASBROUCK HEIGHTS, N.J., Oct. 03, 2018 -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that after long-term safety assessments of repeated Fexapotide.
- Associated Press•2 months ago
Nymox: 2Q Earnings Snapshot
On a per-share basis, the St. Laurent, Quebec-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $88,000 in the period. In the final minutes of trading on Monday, ...
- Associated Press•5 months ago
Nymox: 1Q Earnings Snapshot
On a per-share basis, the St.-Laurent, Quebec-based company said it had a loss of 5 cents. The biopharmaceutical company posted revenue of $152,000 in the period. The company's shares closed at $3.92. ...
- Simply Wall St.•6 months ago
What You Must Know About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) Major Investors
In this article, I’m going to take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Simply Wall St.•6 months ago
Should You Worry About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) CEO Pay?
Leading Nymox Pharmaceutical Corporation (NASDAQ:NYMX) as the CEO, Paul Averback took the company to a valuation of US$236.27M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- Simply Wall St.•7 months ago
Should You Have Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) In Your Portfolio?
For Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NYMX is exposedRead More...
- Simply Wall St.•8 months ago
Interested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Here’s What Its Recent Performance Looks Like
Today I will take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...
- Capital Cube•11 months ago
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis Nymox Pharmaceutical Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Nymox Pharmaceutical Corp. – Abbott Laboratories, Eli Lilly and Company, Quest Diagnostics Incorporated, Pfizer Inc., Johnson & Johnson and Sophiris Bio Inc. (ABT-US, LLY-US, DGX-US, PFE-US, JNJ-US and ... Read more (Read more...)
